Skip to content

Clinical and experimental study on liver autotransplantation for end-stage hepatic alveolar echinococcosis

Clinical and basic research on liver autotransplantation for end-stage hepatic alveolar echinococcosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OO-12002712
Enrollment
Unknown
Registered
2012-11-23
Start date
2012-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic alveolar echinococcosis

Interventions

1:liver autotransplantation

Sponsors

First Affiliated Hospital of Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
10 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. AE lesion invades the retrohepatic inferior vena cava, the first or the second hepatic portal and makes the radical surgery impossible in vivo while the AE-free liver tissue regenerates obviously and its volume reaches 800 ml or above with good function; 2. Eeffective therapy of extrahepatic metastatic AE lesions works by administration of anti-hydatid drugs; 3. To alleviate cholestasis by PTCD or drugs makes the moderate or severe jaundice into mild jaundice.

Exclusion criteria

Exclusion criteria: 1. Multiple liver AE metastasis; 2. The volume of AE-free liver tissue is no less than 800 ml or with poor function; 3. Intractable moderate or severe ascites or systemic sepsis is difficult to be cured; 4. Poor therapeutic effect about extrahepatic metastatic AE lesions by administration of anti-hydatid; 5. Intraabdominal multiple AE lesions or combined with other malignant tumors.

Design outcomes

Primary

MeasureTime frame
Perioperative survival (3 months);Survival(1year and 2 year);

Countries

China

Contacts

Public ContactWen Hao
Dr.wenhao@163.com+86 13609933113

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026